Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib

BACKGROUND: The application of the oral targeted therapeutic agent sorafenib provides new hope for patients suffering from advanced stages of hepatocellular carcinoma (HCC), but the prognosis of such patients remains poor due to the rapid development of the multidrug resistance process in cancer pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhuo, Jiang, Zhengkui, Zhang, Wenzhou, He, Baoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124461/
https://www.ncbi.nlm.nih.gov/pubmed/30214300
http://dx.doi.org/10.2147/CMAR.S167781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124461/
https://www.ncbi.nlm.nih.gov/pubmed/30214300
http://dx.doi.org/10.2147/CMAR.S167781

Ejemplares similares